Abstract: Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.

Abstract: This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.

Abstract: Methods are disclosed for, determining the endocrine responsiveness of breast carcinoma and treating and monitoring the progression of breast carcinoma based on genes which are differentially expressed in breast tumors. Also disclosed are methods for identifying agents useful in the treatment of breast carcinoma, methods for monitoring the efficacy of a treatment for breast carcinoma, methods for inhibiting the proliferation of a breast carcinoma, and breast-specific vectors including the promoters of the disclosed genes.

Abstract: This invention provides methods to predict the likelihood of suicidal or self-destructive behavior in a patient during treatment. The method employs the detection of a polymorphism in the SLC6A3 gene at Exon 9 A59G or a surrogate marker, by various methods. Also provided are methods of treatment based on the presence or absence of this polymorphism or surrogate marker. Also provided are kits to use in the methods of the invention.

Abstract: This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods.

Abstract: This invention provides methods to predict the likelihood of occurrence of the side effect of edema in patients treated with a drug including, but not limited to, a TKI, such as Imatinib or GLEEVEC™/GLIVEC®. The methods employed use gene expression profile comparisons and the determination of specific SNPs and in the IL-1? gene. Methods of treatment of edema and kits for the performance of the above assays are also provided.

Abstract: The present invention provides methods to use expression profiles to determine the bioequivalence of two or more pharmaceutically equivalent drug formulations. In addition, this invention provides methods to select drug formulations that are able to substitute for standard drug formulations without change in clinical efficacy. In other embodiments, this invention provides computer systems, kits and databases for carrying out the methods of the invention.

Abstract: This invention relates to the use of two forms of genomic analysis to predict responsiveness of patients with tyrosine kinase responsive such as Philadelphia chromosome positive leukemia to treatment with tyrosine kinase inhibitor drugs.

Abstract: Methods are disclosed for, determining the endocrine responsiveness of breast carcinoma and treating and monitoring the progression of breast carcinoma based on genes which are differentially expressed in breast tumors. Also disclosed are methods for identifying agents useful in the treatment of breast carcinoma, methods for monitoring the efficacy of a treatment for breast carcinoma, methods for inhibiting the proliferation of a breast carcinoma, and breast-specific vectors including the promoters of the disclosed genes.